Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease (FAME 2)
Source: View publication →
In patients with stable coronary artery disease, FFR-guided percutaneous coronary intervention (PCI) for hemodynamically significant stenoses combined with medical therapy significantly reduced the composite rate of death, myocardial infarction, or urgent revascularization compared to medical therapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The FAME 2 trial established fractional flow reserve (FFR) as a crucial tool for risk-stratifying patients with stable coronary artery disease. It demonstrated that performing PCI on hemodynamically significant lesions (FFR <= 0.80) effectively prevents future urgent revascularizations, while deferring PCI on non-ischemic lesions and treating them with optimal medical therapy alone is safe and yields excellent clinical outcomes.
Historical Context
Following the 2007 COURAGE trial, which demonstrated no mortality or MI benefit to routine PCI over medical therapy in stable coronary artery disease, there was a major paradigm shift toward conservative management. Simultaneously, the FAME 1 trial (2009) established that FFR-guided PCI yielded superior outcomes compared to angiography-guided PCI in multivessel disease. FAME 2 sought to bridge these findings, testing whether PCI provides incremental benefit over medical therapy specifically when restricted to physiologically significant, ischemia-producing lesions.
Guided Discussion
High-yield insights from every perspective
How does Fractional Flow Reserve (FFR) differ from anatomical assessment (like angiographic percentage of stenosis) in evaluating stable coronary artery disease, and what is the physiological principle behind administering a hyperemic agent like adenosine during the measurement?
Key Response
Angiography only provides a 2D anatomical silhouette of a stenosis, which often correlates poorly with actual ischemia. FFR measures the pressure drop across a lesion (Pd/Pa) under conditions of maximal hyperemia (induced by adenosine) to calculate the fraction of normal maximal coronary flow. This isolates the physiological impact of the specific epicardial stenosis from microvascular resistance.
In the FAME 2 trial, the primary endpoint was driven by a reduction in urgent revascularization rather than hard endpoints like death or MI. How should this influence your counseling of a patient with stable angina and an FFR-positive lesion regarding the expected benefits of PCI versus optimal medical therapy?
Key Response
Residents need to understand that in stable CAD, FFR-guided PCI does not necessarily prevent death or MI compared to optimal medical therapy. Counseling should focus on symptom relief and preventing the need for future unplanned hospital visits for refractory angina, rather than suggesting the stent will prolong life or prevent a myocardial infarction.
The FAME 2 trial was halted early by the Data and Safety Monitoring Board (DSMB) due to a highly significant difference in the primary endpoint. What are the potential statistical and clinical pitfalls of truncating a cardiovascular outcomes trial early for benefit, specifically regarding the estimation of treatment effect size?
Key Response
Trials stopped early for benefit often overestimate the true treatment effect, a phenomenon known as random high bias or truncation bias. Fellows must recognize that the dramatic reduction in urgent revascularizations might be exaggerated compared to what would be seen if the trial ran to its full planned duration, potentially skewing the long-term risk-benefit analysis.
FAME 2 demonstrated that leaving an FFR-positive lesion untreated with OMT alone leads to higher rates of urgent revascularization. As an attending, how do you integrate these findings with the ISCHEMIA trial results to optimize shared decision-making for patients with stable CAD and moderate-to-severe ischemia?
Key Response
Attendings must reconcile FAME 2, which supports PCI for FFR less than or equal to 0.80 to reduce urgent revascularization, with ISCHEMIA, which showed an initial conservative strategy was non-inferior for hard outcomes. The teaching point is that while an initial conservative strategy is safe, identifying hemodynamically significant lesions helps predict who is more likely to require urgent intervention, making PCI a reasonable upfront choice for symptom control and reducing readmissions.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The FAME 2 primary composite endpoint included urgent revascularization, an outcome highly sensitive to physician subjectivity, particularly since physicians were not blinded to the FFR results. How does this lack of blinding introduce ascertainment bias, and what trial design modifications could have mitigated this threat to validity?
Key Response
Since patients and physicians knew the FFR values and treatment assignment, a patient presenting with chest pain in the OMT group might be more readily sent for urgent revascularization because the physician knows there is an untreated FFR-positive lesion. A sham-controlled design, similar to ORBITA, or strict, blinded adjudication of clinical necessity using objective biomarker criteria would have mitigated this ascertainment bias.
As a peer reviewer examining the FAME 2 manuscript, how would you evaluate the inclusion of urgent revascularization alongside hard clinical endpoints in the primary composite outcome, and what specific supplementary data would you request to ensure the event was truly urgent rather than a deferred elective procedure?
Key Response
Composite endpoints mixing subjective, softer outcomes with hard outcomes can be misleading. A reviewer must flag that the trial's success hinged entirely on this soft endpoint. I would request detailed supplementary data on the exact clinical presentation, such as troponin levels and dynamic ECG changes, for every urgent revascularization event to ensure it was not driven by patient or physician anxiety about a known untreated lesion.
Current guidelines emphasize optimal medical therapy as the first-line treatment for stable CAD. Based on FAME 2 demonstrating a reduction in urgent revascularization but no mortality benefit, how should guidelines grade the recommendation for routine use of FFR in guiding PCI for stable patients with intermediate stenoses?
Key Response
The ACC/AHA and ESC guidelines incorporate FFR to guide revascularization in intermediate stenoses as a Class 1 recommendation. The committee must balance the FAME 2 data showing clear physiological benefit through reduced urgent revascularization against the lack of survival benefit, reinforcing that FFR is essential to prevent inappropriate stenting of non-ischemic lesions while validating PCI for symptom control, without mischaracterizing it as a life-saving intervention.
Clinical Landscape
Noteworthy Related Trials
COURAGE Trial
Tested
PCI plus Optimal Medical Therapy (OMT)
Population
Patients with stable coronary artery disease
Comparator
Optimal Medical Therapy (OMT) alone
Endpoint
Composite of death from any cause and nonfatal myocardial infarction
FAME Trial
Tested
FFR-guided PCI
Population
Patients with multivessel coronary artery disease
Comparator
Angiography-guided PCI
Endpoint
Rate of death, nonfatal MI, and repeat revascularization at 1 year
ISCHEMIA Trial
Tested
Initial invasive strategy (angiography and revascularization) plus OMT
Population
Patients with stable coronary disease and moderate or severe ischemia
Comparator
Conservative strategy (OMT alone)
Endpoint
Composite of cardiovascular death, MI, resuscitated cardiac arrest, heart failure, or unstable angina
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis